title: Phase II trial of a combination of cyclosphamide, vincristine, and methotrexate in advanced colorectal carcinoma.
abstract: Twenty patients with advanced colon cancer were treated with a combination of low-dose weekly cyclophosphamide, vincristine, and methotrexate (COM) after demonstrated progression of disease with 5-fluorouracil (5-FU). Four patients (20%) had partial responses with a median survival of 15 months, six (30%) had disease stabilization for 3--16 months (median survival, 8 months), and ten progressed with a median survival of 5.5 months. All four partial responses and five of six stabilizations occurred in patients with a performance status of 0 or 1. COM appeared well-tolerated and at least as effective as alternative secondary chemotherapy following 5-FU failure.
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate